---
layout: default
title: Lidocaine Hcl
parent: 僅模型預測 (L5)
nav_order: 203
evidence_level: L5
indication_count: 0
---

# Lidocaine Hcl
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# LIDOCAINE HCL: Local Anesthetic / Antiarrhythmic — No TxGNN Repurposing Predictions Generated

## One-Sentence Summary

Lidocaine HCl is a widely used local anesthetic and antiarrhythmic agent with **21 registered products** in Malaysia.
The current TxGNN analysis run **did not generate any repurposing predictions** for this compound,
and critical data gaps in mechanism of action, approved indications, and safety information prevent a complete evaluation at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not retrieved in current dataset |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 – No model prediction output |
| Malaysia Market Status | ✓ Marketed |
| Number of Registrations | 21 |
| Recommended Decision | Hold |

---

## Why Is No Prediction Available?

TxGNN requires a valid **DrugBank ID** to anchor a compound in the knowledge graph and generate repurposing scores. In this Evidence Pack, `drugbank_id` is `null`, meaning the pipeline could not map Lidocaine HCl to a knowledge graph node. Without this anchor, the model produces no ranked disease candidates.

Additionally, the `original_indications` array is empty and `original_moa` is unavailable, removing the biological context needed to validate any mechanistic rationale even if predictions were present.

> Currently, detailed mechanism of action data is not available. Based on general pharmacological knowledge, Lidocaine HCl is a sodium channel blocker used as a local anesthetic and Class Ib antiarrhythmic drug; however, this information was not confirmed in the supplied Evidence Pack and should not be used for formal evaluation without verified sourcing.

---

## Clinical Trial Evidence

Currently no related clinical trials registered *(no predicted indication to search against)*.

---

## Literature Evidence

Currently no related literature available *(no predicted indication to search against)*.

---

## Malaysia Market Information

A total of **21 registered products** were identified via NPRA query (query date: 2026-03-27). However, individual license details — including authorization number, product name, dosage form, and approved indication text — were not retrieved in the current dataset.

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------------------|-------------|-------------|---------------------|
| — | — | — | Detailed records not available; 21 registrations confirmed by NPRA |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This evaluation cannot proceed meaningfully because the TxGNN pipeline produced no repurposing candidates — a direct consequence of the missing DrugBank ID — and all drug-level data fields (original indication, mechanism of action, safety warnings, contraindications, and individual license records) are absent from the current Evidence Pack.

**To proceed, the following is needed:**

- **Resolve DrugBank ID**: Look up Lidocaine HCl on [DrugBank](https://www.drugbank.ca) (expected: DB00281) and update the `drugbank_id` field, then re-run the TxGNN prediction pipeline
- **Retrieve NPRA license details**: Query NPRA product registry for all 21 registrations to populate product names, dosage forms, and approved indication texts
- **Obtain MOA and safety data**: Pull the DrugBank entry for pharmacodynamics, mechanism of action, warnings, contraindications, and drug–drug interactions
- **Parse package inserts**: Download NPRA/manufacturer-approved prescribing information PDFs to confirm local warnings and contraindications (Data Gap DG001 — severity: Blocking)
- **Re-run evidence collection**: Once a predicted indication is confirmed, trigger ClinicalTrials.gov and PubMed collectors to gather supporting literature

> ⚠️ **YMYL Disclaimer**: This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate must undergo clinical validation before application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

